This paper reviews the clinical evidence comparing dabigatran (Pradaxa) and warfarin (Coumadin) as anticoagulants for stroke and systemic embolism prevention in patients with atrial fibrillation (AF). Drawing on phase 2 and phase 3 clinical trials, the review examines dosing effects, bleeding risks, patient compliance, and quality-of-care considerations. Key studies analyzed include the PETRO trial (Ezekowitz et al., 2007), a head-to-head comparison by Schulman et al. (2009), the large RE-LY phase III trial (Connolly et al., 2009), and a retrospective quality-of-care analysis by Wallentin et al. (2010). The paper concludes that 150 mg dabigatran twice daily is at least as effective as warfarin in reducing stroke risk, though safety concerns — particularly gastrointestinal bleeding and dyspepsia — warrant further investigation before dabigatran can be adopted as the universal anticoagulant of choice.
This study guide is drawn from PaperDue's library of 130,000+ paper examples across 47 subjects.
The paper demonstrates effective comparative literature synthesis: rather than summarizing each study in isolation, the author cross-references findings across studies to identify convergent conclusions and contradictions. For example, the gastrointestinal bleeding concern identified in Connolly et al. is revisited and deepened by Wallentin et al.'s quality-of-care analysis, showing how subsequent research can recontextualize earlier results.
The paper opens with background on both drugs and the clinical context of atrial fibrillation, then moves through four key studies in roughly chronological and increasing scale order. Each study section covers design, primary outcomes, safety outcomes, and limitations. The final section synthesizes findings across all studies to arrive at a qualified clinical recommendation, appropriately hedged by remaining safety uncertainties.
After more than five decades as the preferred anticoagulant worldwide, warfarin is being challenged by a new rival that does not require careful dosage monitoring. Pradaxa (dabigatran) was unanimously approved by the FDA on October 19, 2010, for treating atrial fibrillation (AF) patients who are at an increased risk for suffering stroke and systemic embolisms (U.S. Food and Drug Administration). Dabigatran acts by binding directly to thrombin. Warfarin (Coumadin) is an anticoagulant that functions by inhibiting the synthesis of vitamin K-dependent clotting factors (Lemos et al., 770–771).
Variations in the levels of vitamin K in the diet can influence how effective a given dose of warfarin is for a patient, so appropriate therapeutic dosages are determined on an individual basis periodically through a standardized clotting test known as the international normalized ratio (INR). Even though warfarin can reduce the risk of stroke in AF patients by as much as 68%, patient compliance with treatment — measured as time in therapeutic range (TTR) — is a significant problem because of the requisite periodic monitoring of dose effectiveness and the risk of major bleeding events (Ezekowitz, 2007). Because dabigatran does not require the labor- and time-intensive monitoring that warfarin does, the expectation is that patient compliance should increase.
Atrial fibrillation increases the risk of stroke and systemic embolisms because the upper chambers of the heart begin to beat irregularly, thus impairing blood flow efficiency. Slowed blood flow can result in blood pooling in the heart chambers, and clots can form. If these clots enter the brain, they could cause a stroke. For this reason, AF patients are often prescribed anticoagulants to help prevent clot formation. The prevalence of AF in the United States increases from less than 1% for persons under the age of 60 to over 10% for persons over 80 (Centers for Disease Control and Prevention [CDC], 2003). Deaths linked to AF affect about 1 in 4,000 people each year, but 84% occur in people over the age of 75.
Atrial fibrillation patients often suffer from coronary artery disease, so the focus of a dabigatran phase 2 clinical trial was to determine the safety of combining this anticoagulant with aspirin (Ezekowitz et al., 2007). Three dabigatran doses were administered (50, 150, and 300 mg twice daily) to patients for 12 weeks, alone or in combination with 81 or 325 mg aspirin, thus creating nine experimental groups. Patients treated with warfarin (INR = 2.0–3.0) were used as a control.
The primary outcome of concern was bleeding events. Results indicated that major bleeding events (6% increase, p < 0.02) or all types of bleeding events (26% increase, p = 0.0003) occurred more often in patients treated with 300 mg dabigatran twice daily plus aspirin. On the other end of the dosage spectrum, 50 mg dabigatran was less likely to cause bleeding than all other conditions (15% increase vs. 300 mg, p = 0.0002; 11% increase vs. 150 mg, p = 0.01; 11% increase vs. warfarin, p = 0.044). However, the two embolisms that occurred during the study happened in patients taking 50 mg dabigatran twice daily, alone or with 81 mg of aspirin. This result indicates that 50 mg dabigatran, with or without 81 mg of aspirin, does not provide effective protection against stroke or systemic embolisms.
This possibility was supported by the finding that plasma D-dimer levels were inversely correlated with dabigatran dose (13% increase at 50 mg, p = 0.0008; 3% increase at 150 mg, p = 0.027; 300 mg, p = 0.267) when compared to warfarin. The results of this study suggest that 150 mg dabigatran twice daily is a relatively safe and effective dose for coronary artery patients taking aspirin. This conclusion is limited by the small sample size (502), consisting mostly of men (411), which precludes making stronger statements about safety and efficacy for the general population.
You’re 29% through this paper. Sign up to read the remaining 4 sections.
Sign Up Now — Instant Access Already a member? Log inAlways verify citation format against your institution’s current style guide requirements.